

Prof Manuela Iezzi.

<http://orcid.org/0000-0002-6296-6498>

CURRENT POSITION: Associate Professor in Anatomic Pathology, Department of Medicine and Translational Sciences, G. d'Annunzio University of Chieti-Pescara.

WORK ADDRESS: Center for Advanced Studies and Technology (CAST), Via Luigi Polacchi 11-13, 66100, Chieti, Italy. Tel +39-0871-541546 (Room) Tel +39-0871-541570 (Lab) e-mail: manuela.iezzi1@unich.it

EDUCATION:

- 1998 Medical degree at University "G. D'Annunzio" Chieti-Pescara, Italy. Final score 110/110 cum laude.
- 2003 Specialization in Pathology at University "G. D'Annunzio" Chieti-Pescara, Italy (Director Prof Piero Musiani). Final score 70/70 cum laude.
- 2007 PhD in Oncology and Molecular Pathology at University "G. D'Annunzio" Chieti-Pescara, Italy (Director Prof Stefano Iacobelli)

EMPLOYMENT:

- 2008 Research Contract from G. d'Annunzio University of Chieti-Pescara
- 2008 Researcher in Anatomic Pathology at the G. d'Annunzio University of Chieti-Pescara
- 2016 Associate Professor in Anatomic Pathology at the G. d'Annunzio University of Chieti-Pescara

RESEARCH INTERESTS

Manuela Iezzi began her research activity in the Immuno-Oncology Laboratory directed by Piero Musiani, a pathologist with a strong passion for research. In his laboratory she learned to apply technical tools and competences of anatomic pathology to develop a morpho-functional image of tumor and tumor microenvironment.

During the years of Anatomic Pathology specialty course and PhD course in Molecular Pathology, Dr Iezzi coupled the study of human pathology with that of murine models of disease acquiring competencies in comparative pathology.

She developed several new techniques to better study and characterize murine models of mammary cancer and their immune environment like Whole Mount preparations, multiparametric confocal microscopy and three-dimensional reconstruction, intracardiac perfusion and staining of vessel tree. She became a leading figure for the characterization of murine cancer models (particularly focusing on mammary and prostate cancer) and successfully cooperated with several national and

international prestigious research groups for the characterization of cancer murine models and the research of anti-cancer immune-therapies.

In the last ten years, her research activity has been articulated in the following research lines:

1. Cancer immunology and anti-cancer immunotherapies

- 1- Fiore A et al. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat Commun.* 2018 Dec 5;9(1):5193.
- 2- Bartolacci C et al. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer. *Cancer Immunol Res.* 2018 Dec;6(12):1486-1498.
- 3- Sara Sandri et al. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget* 2017
- 4- Bandini S et al. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. *Oncoimmunology.* 2016 Nov 8;5(12):e1253653.
- 5- Sandri S et al. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. *Cancer Res.* 2016 May 1;76(9):2540-51.
- 6- Lamolinara A et al. Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor. *J Immunol Res.* 2015; 2015:159145.
- 7- Barutello G et al. Antitumor immunization of mothers delays tumor development in cancer-prone offspring. *Oncoimmunology.* 2015 Feb 3;4(5):e1005500. eCollection 2015 May.
- 8- Croci S et al. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. *Breast Cancer Res.* 2015 May 22;17:70
- 9- Macagno M et al. Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. *J Immunol.* 2014 Jun 1;192(11):5434-41.
- 10- De Giovanni C et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. *Breast Cancer Res.* 2014 Jan 23;16(1):R10.
- 11- Silvio Bandini et al. Early onset and enhanced growth of autochthonous mammary carcinomas in C3 deficient Her2/neu transgenic mice. *Oncoimmunology.* 2013 Sep 1;2(9):e26137.

- 12- Nanni P et al. Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. *PLoS Pathog.* 2013 Jan;9(1):e1003155.
- 13- De Giovanni C et al. Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. *British Journal of Cancer* 2012 Oct 9;107(8):1302-9.
- 14- Iezzi M et al. DNA vaccination against oncoantigens: A promise. *Oncoimmunology.* 2012 May 1;1(3):316-325.
- 15- Arigoni M et al. A vaccine targeting angiominin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. *Angiogenesis.* 2012 Jun;15(2):305-16.
- 16- Berta GN et al. A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. *Cancer Prev Res (Phila).* 2011 Jul;4(7):994-1001.
- 17- Rolla S et al. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. *J Immunol.* 2010 Jun 1;184(11):6124-32.
- 18- Quagliano E et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. *Cancer Res.* 2010 Apr 1;70(7):2604-12.
- 19- Ugel S et al. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. *Blood.* 2010 Feb 18;115(7):1374-84.
- 20- De Giovanni C et al. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. *Vaccine.* 2009 Mar 23;27(14):2065-9.
- 21- De Giovanni C et al. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. *Hum Gene Ther.* 2009 May;20(5):453-64.

2. Molecular mechanisms of tumor pathology.

- 22- Grasso S et al. The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. *Cell Death Differ.* 2019 Jul 8. doi: 10.1038/s41418-019-0386-6.
- 23- De Cola A et al. MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells. *Cell Death Dis.* 2018 Jul 26;9(8):821.

- 24- Castiello L et al. Disruption of IFN-I signaling promotes HER2/neu tumor progression and breast cancer stem cells. *Cancer Immunol Res.* 2018 Jun;6(6):658-670.
- 25- Palladini A et al. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. *Oncotarget.* 2017 Apr 13.
- 26- Grasso S et al. The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. *Nat Commun.* 2017 Mar 16;8:14797.
- 27- Andreani C et al. Resveratrol fuels HER2 and ER α -positive breast cancer behaving as proteasome inhibitor. *Aging (Albany NY).* 2017 Feb 26;9(2):508-523.
- 28- Castagnoli L et al. Pathobiological implications of the Δ 16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. *Oncogene.* 2017 Mar 23;36(12):1721-1732.
- 29- Tilio M et al. Irreversible inhibition of Δ 16HER2 is necessary to suppress Δ 16HER2-positive breast carcinomas resistant to Lapatinib. *Cancer Lett.* 2016 Oct 10;381(1):76-84.
- 30- Chikh A et al. Class II phosphoinositide 3-kinase C2 β regulates a novel signaling pathway involved in breast cancer progression. *Oncotarget.* 2016 Feb 26.
- 31- Manservigi F et al. Effect of maternal exposure to endocrine disrupting chemicals on reproduction and mammary gland development in female sprague-dawley rats. *Reprod Toxicol.* 2014 Dec 29.
- 32- Steven A et al. HER-2/neu mediates oncogenic transformation via altered CREB expression and function. *Mol Cancer Res.* 2013 Sep 11.
- 33- Bisaro B et al. p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. *Breast Cancer Res.* 2012 Oct 26;14(5):R137.
- 34- Marchini C et al. The human splice variant Δ 16HER2 induces rapid tumor onset in a reporter transgenic mouse. *PLoS One.* 2011 Apr 29;6(4):e18727.
- 35- Cabodi S et al. p130Cas is an essential transducer element in ErbB2 transformation. *FASEB J.* 2010 Oct;24(10):3796-808.
- 36- Ciruolo E et al. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. *Mol Biol Cell.* 2010 Mar 1;21(5):704-11.

3. Identification, validation and clinical translation of new targets for anticancer therapy, new drugs and methods for early diagnosis of cancer

- 37- Koschorke A et al. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cell Oncol (Dordr)*. 2019 Aug 2
- 38- Ferrauto G et al. Generation of multiparametric MRI maps by using Gd-labelled- RBCs reveals phenotypes and stages of murine prostate cancer. *Sci Rep*. 2018 Jul 12;8(1):10567.
- 39- Gambini V et al. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer. *Eur J Med Chem*. 2018 Jun 2;155:418-427.
- 40- Capone E et al. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. *J Control Release*. 2018 Mar 14.
- 41- Capone E et al. EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. *Oncotarget*. 2017 Sep 8;8(56):95412-95424.
- 42- Montani M et al. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells. *Pharmacol Res*. 2016 Mar 30;107:282-290.
- 43- Mosley M et al. Claudin-4 SPECT Imaging Allows Detection of Aplastic Lesions in a Mouse Model of Breast Cancer. *J Nucl Med*. 2015 May;56(5):745-51.
- 44- Cornelissen B et al. Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer. *J Nucl Med*. 2014 Dec;55(12):2026-31.
- 45- Riccardo F et al. Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. *BMC Genomics*. 2014;15 Suppl 3:S1.
- 46- Kalogris C et al. Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. *Biochem Pharmacol*. 2014 May 27.
- 47- Conti L et al. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding $\alpha\text{v}\beta\text{3}$ integrins. *Contrast Media Mol Imaging*. 2013 Jul-Aug;8(4):350-60.

- 48- Nanni P et al. Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(-/-);Il2rg(-/-) Mice and Treatment with PI3K Inhibitor. PLoS One. 2012;7(6):e39626. Epub 2012 Jun 21.
- 49- Iezzi M et al. HCG hastens both the development of mammary carcinoma and the metastatization of HCG/LH and ERBB-2 receptor-positive cells in mice. Int J Immunopathol Pharmacol. 2011 Jul-Sep;24(3):621-30.
- 50- Pannellini T et al. A dietary tomato supplement prevents prostate cancer in TRAMP mice. Cancer Prev Res (Phila). 2010 Oct;3(10):1284-91.
- 51- Bono AV et al. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. Anal Quant Cytol Histol. 2010 Jun;32(3):136-45.
- 52- De Santis R et al. AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. Cancer Biother Radiopharm. 2010 Apr;25(2):143-8.
- 53- Coscia M et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010 Dec;14(12):2803-15.

4. Identification and validation of new prognostic and predictive markers.

- 54- Lattanzio R et al. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. BMC Cancer. 2019 Jul 30;19(1):747.
- 55- Corda G et al. Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. J Pathol. 2017 Feb;241(3):350-361.
- 56- Marchetti A et al. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. J Thorac Oncol. 2016 Apr;11(4):487-95.
- 57- Castagnoli L et al. Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. Cancer Res. 2014 Nov 1;74(21):6248-59

58- Chiari R et al. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. *Clin Lung Cancer*. 2014 Nov;15(6):470-4.

59- Marchini C et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. *PLoS One*. 2010 Nov 30;5(11):e14131.

5. Drug repositioning

60- Bibbo' S et al. Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. *Oncogenesis*. 2020 Jan 2;9(1):3.

61- Mottini C et al. Predictive signatures inform the effective repurposing of Decitabine to treat K-RAS-dependent Pancreatic Ductal Adenocarcinoma. *Cancer Res*. 2019 Sep 5.

62- Carrella D et al. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. *Oncotarget*. 2016 Aug 16

63- Inflammation

64- Giuliani C et al. Resveratrol has anti-thyroid effects both in vitro and in vivo. *Food Chem Toxicol*. 2017 Sep;107(Pt A):237-247.

65- Codagnone M et al. Resolvin D1 enhances the resolution of lung inflammation caused by long-term *Pseudomonas aeruginosa* infection. *Mucosal Immunol*. 2017 Apr 19.

66- Petrarca C et al. rBet v 1 immunotherapy of sensitized mice with *Streptococcus thermophilus* as vehicle and adjuvant. *Hum Vaccin Immunother*. 2014 Mar 6;10(5).

67- Nubile M et al. Expression of CREB in Primary Pterygium and Correlation with Cyclin D1, ki-67, MMP7, p53, p63, Survivin and Vimentin. *L. Ophthalmic Res*. 2013;50(2):99-107.

68- Nubile M et al. Pathological changes of the anatomical structure and markers of the limbal stem cell niche due to inflammation. *Mol Vis*. 2013;19:516-25. Epub 2013 Feb 26.

69- Petrarca C et al. Monomeric allergoid intragastric administration induces local and systemic tolerogenic response involving IL-10-producing CD4(+)CD25(+) T regulatory cells in mice. *Int J Immunopathol Pharmacol*. 2010 Oct-Dec;23(4):1021-31.

SCIENTIFIC PUBLICATIONS

The original peer-reviewed publications are 110, the citations obtained are 3366 (source: Scopus), h Index = 32 (source: Scopus)

Chapters in books

Rossano Lattanzio, Alessia Lamolinara, Mauro Piantelli and Manuela Iezzi

"Natural compounds, antioxidant, and antiandrogens in the prevention of prostate cancer: in vivo evidences from murine models and human clinical studies." in "Prostate Cancer", ISBN 980-953-307-719-7. 2013

Cristina Marchini, Lucia Pietrella, Cristina Kalogris, Chiara Garulli, Federico Gabrielli, Elena Quaglino, Manuela Iezzi, Maura Montani, Serenella M. Pupa, Elda Tagliabue and Augusto Amici. "HER2-driven carcinogenesis: new mouse models for novel immunotherapies" in "Oncogene" ISBN 978-953-51-0858-0. 2013

Iezzi M Calogero RA, Spadaro M, Musiani P, Forni G. and Cavallo F. "BALB NeuT female mice as a dynamic model of mammary cancer." In K Wang Ed . Animal Models of Diseases:

Translational Animal Models in Drug Discovery and Development, 2012, 139-166. ISBN 9781608054695

Papers in International Journals

1. Bibbo' S, Lamolinara A, Capone E, Purgato S, Tsakaneli A, Panella V, Sallese M, Rossi C, Ciufici P, Nieddu V, De Laurenzi V, Iezzi M, Perini G, Sala G, Sala A. Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. *Oncogenesis*. 2020 Jan 2;9(1):3. doi: 10.1038/s41389-019-0186-3. PMID: 31900399
2. Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Trisciuglio D, Iuliano A, Del Bufalo D, di Bernardo D, Melisi D, Draetta GF, Ciliberto G, Carugo A, Cardone L. Predictive signatures inform the effective repurposing of Decitabine to treat K-RAS-dependent Pancreatic

Ductal Adenocarcinoma. *Cancer Res.* 2019 Sep 5. pii: canres.0187.2019. doi: 10.1158/0008-5472.CAN-19-0187. [Epub ahead of print] PubMed PMID: 31492820.

3. Koschorke A, Faraci S, Giani D, Chiodoni C, Iorio E, Canese R, Colombo MP, Lamolinara A, Iezzi M, Ladomery M, Vernieri C, de Braud F, Di Nicola M, Tagliabue E, Castagnoli L, Pupa SM. Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. *Cell Oncol (Dordr)*. 2019 Aug 2. doi: 10.1007/s13402-019-00464-w. [Epub ahead of print] PubMed PMID: 31376137.
4. Lattanzio R, Iezzi M, Sala G, Tinari N, Falasca M, Alberti S, Buglioni S, Mottolese M, Perracchio L, Natali PG, Piantelli M. PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. *BMC Cancer*. 2019 Jul 30;19(1):747. doi:10.1186/s12885-019-5949-x. PubMed PMID: 31362705; PubMed Central PMCID: PMC6668079.
5. Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P. The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. *Cell Death Differ*. 2019 Jul 8. doi: 10.1038/s41418-019-0386-6. [Epub ahead of print] Erratum in: *Cell Death Differ*. 2019 Sep 5;:. PubMed PMID: 31285546.
6. Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Biciato S, Blazar BR, Sahin U, Murray PJ, Bronte V. Induction of immunosuppressive functions and NF- κ B by FLIP in monocytes. *Nat Commun*. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4. PubMed PMID: 30518925; PubMed Central PMCID: PMC6281604.
7. Bartolacci C, Andreani C, Curcio C, Occhipinti S, Massaccesi L, Giovarelli M, Galeazzi R, Iezzi M, Tilio M, Gambini V, Wang J, Marchini C, Amici A. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer. *Cancer Immunol Res*. 2018 Dec;6(12):1486-1498. doi: 10.1158/2326-6066.CIR-18-0179. Epub 2018 Oct 16. PubMed PMID: 30327365.
8. De Cola A, Lamolinara A, Lanuti P, Rossi C, Iezzi M, Marchisio M, Todaro M, De Laurenzi V. MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells. *Cell*

Death Dis. 2018 Jul 26;9(8):821. doi: 10.1038/s41419-018-0854-9. PubMed PMID: 30050081; PubMed Central PMCID: PMC6062508.

9. Ferrauto G, Di Gregorio E, Lanzardo S, Ciolli L, Iezzi M, Aime S. Generation of multiparametric MRI maps by using Gd-labelled- RBCs reveals phenotypes and stages of murine prostate cancer. *Sci Rep*. 2018 Jul 12;8(1):10567. doi: 10.1038/s41598-018-28926-5. PubMed PMID: 30002426; PubMed Central PMCID: PMC6043588.
10. Gambini V, Tilio M, Maina EW, Andreani C, Bartolacci C, Wang J, Iezzi M, Ferraro S, Ramadori AT, Simon OC, Pucciarelli S, Wu G, Dou QP, Marchini C, Galassi R, Amici A. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer. *Eur J Med Chem*. 2018 Jun 2;155:418-427. doi: 10.1016/j.ejmech.2018.06.002. [Epub ahead of print] PubMed PMID: 29906688.
11. Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Arico E. Disruption of IFN-I signaling promotes HER2/neu tumor progression and breast cancer stem cells. *Cancer Immunol Res*. 2018 Apr 5.
12. Capone E, Lamolinara A, D'Agostino D, Rossi C, De Laurenzi V, Iezzi M, Iacobelli S, Sala G. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. *J Control Release*. 2018 Mar 14.
13. Capone E, Giansanti F, Ponziani S, Lamolinara A, Iezzi M, Cimini A, Angelucci F, Sorda R, Laurenzi V, Natali PG, Ippoliti R, Iacobelli S, Sala G. EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma. *Oncotarget*. 2017 Sep 8;8(56):95412-95424.
14. Giuliani C, Iezzi M, Ciolli L, Hysi A, Bucci I, Di Santo S, Rossi C, Zucchelli M, Napolitano G. Resveratrol has anti-thyroid effects both in vitro and in vivo. *Food Chem Toxicol*. 2017 Sep;107(Pt A):237-247. doi: 10.1016/j.fct.2017.06.044. Epub 2017 Jun 28. PubMed PMID: 28668442.
15. Sara Sandri, Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Ornella Poffe, Rosalinda Trovato, Alessandra Fiore, Sara Sartori, Andrea Sbarbati, Attilio Bondanza, Simone Cesaro, Mauro Krampera, Maria T. Scupoli, Michael I. Nishimura, Manuela Iezzi, Silvia Sartoris, Vincenzo Bronte and Stefano Ugel. Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. *Oncotarget* 2017
16. Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C,

- Tagliabue E, Iezzi M, Nanni P, Lollini PL. HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response. *Oncotarget*. 2017 Apr 13. doi: 10.18632/oncotarget.17088. [Epub ahead of print] PubMed PMID: 28467963.
17. Codagnone M, Cianci E, Lamolinara A, Mari VC, Nespoli A, Isopi E, Mattoscio D, Arita M, Bragonzi A, Iezzi M, Romano M, Recchiuti A. Resolvin D1 enhances the resolution of lung inflammation caused by long-term *Pseudomonas aeruginosa* infection. *Mucosal Immunol*. 2017 Apr 19. doi: 10.1038/mi.2017.36. [Epub ahead of print] PubMed PMID: 28422188.
 18. Grasso S, Chapelle J, Salemme V, Aramu S, Russo I, Vitale N, Verdun di Cantogno L, Dallaglio K, Castellano I, Amici A, Centonze G, Sharma N, Lunardi S, Cabodi S, Cavallo F, Lamolinara A, Stramucci L, Moiso E, Provero P, Albini A, Sapino A, Staaf J, Di Fiore PP, Bertalot G, Pece S, Tosoni D, Confalonieri S, Iezzi M, Di Stefano P, Turco E, Defilippi P. The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. *Nat Commun*. 2017 Mar 16;8:14797. doi: 10.1038/ncomms14797. PubMed PMID: 28300085; PubMed Central PMCID: PMC5357316.
 19. Andreani C, Bartolacci C, Wijnant K, Crinelli R, Bianchi M, Magnani M, Hysi A, Iezzi M, Amici A, Marchini C. Resveratrol fuels HER2 and ER α -positive breast cancer behaving as proteasome inhibitor. *Aging (Albany NY)*. 2017 Feb 26;9(2):508-523. doi: 10.18632/aging.101175. PubMed PMID: 28238967; PubMed Central PMCID: PMC5361678.
 20. Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, Lamolinara A, Mirza H, Barcaroli D, Ermler S, Silva E, Yasaei H, Newbold RF, Vagnarelli P, Mottolese M, Natali PG, Perracchio L, Quist J, Grigoriadis A, Marra P, Tutt AN, Piantelli M, Iacobelli S, De Laurenzi V, Sala A. Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. *J Pathol*. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29. PubMed PMID: 27859262; PubMed Central PMCID: PMC5248601.
 21. Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. *Oncogene*. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19. PubMed PMID: 27641338.
 22. Bandini S, Macagno M, Hysi A, Lanzardo S, Conti L, Bello A, Riccardo F, Ruiu R, Merighi IF, Forni G, Iezzi M, Quagliano E, Cavallo F. The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. *Oncoimmunology*. 2016 Nov 8;5(12):e1253653. doi:

10.1080/2162402X.2016.1253653. eCollection 2016. PubMed PMID: 28123895; PubMed Central PMCID: PMC5214935.

23. Carrella D, Manni I, Tumaini B, Dattilo R, Papaccio F, Mutarelli M, Sirci F, Amoreo CA, Mottolese M, Iezzi M, Ciolli L, Aria V, Bosotti R, Isacchi A, Loreni F, Bardelli A, Avvedimento VE, di Bernardo D, Cardone L. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. *Oncotarget*. 2016 Aug 16. doi: 10.18632/oncotarget.11318. PubMed PMID: 27542212.
24. Tilio M, Gambini V, Wang J, Garulli C, Kalogris C, Andreani C, Bartolacci C, Elempuru Zabaleta M, Pietrella L, Hysi A, Iezzi M, Belletti B, Orlando F, Provinciali M, Galeazzi R, Marchini C, Amici A. Irreversible inhibition of Δ 16HER2 is necessary to suppress Δ 16HER2-positive breast carcinomas resistant to Lapatinib. *Cancer Lett*. 2016 Oct 10;381(1):76-84. doi: 10.1016/j.canlet.2016.07.028. Epub 2016 Jul 27. PubMed PMID: 27475932.
25. Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S. Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. *Cancer Res*. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318. PubMed PMID: 27197263.
26. Montani M, Pazmay GV, Hysi A, Lupidi G, Pettinari R, Gambini V, Tilio M, Marchetti F, Pettinari C, Ferraro S, Iezzi M, Marchini C, Amici A. The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells. *Pharmacol Res*. 2016 Mar 30;107:282-290. doi: 10.1016/j.phrs.2016.03.032. PubMed PMID: 27038531.
27. Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, Lattanzio R, Broggin M, Piantelli M, Maffucci T, Falasca M. Class II phosphoinositide 3-kinase C2 β regulates a novel signaling pathway involved in breast cancer progression. *Oncotarget*. 2016 Feb 26. doi: 10.18632/oncotarget.7761. [Epub ahead of print] PubMed PMID: 26934321.
28. Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, Filice G, Guetti L, Mucilli F, Buttitta F. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm. *J Thorac Oncol*. 2016 Apr;11(4):487-95. doi: 10.1016/j.jtho.2015.12.111. Epub 2016 Feb 22. PubMed PMID: 26916631.

29. Lamolinara A, Stramucci L, Hysi A, Iezzi M, Marchini C, Mariotti M, Amici A, Curcio C. Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor. *J Immunol Res.* 2015; 2015:159145. doi: 10.1155/2015/159145. Epub 2015 Jul 13. PubMed PMID: 26247038.
30. Barutello G, Curcio C, Spadaro M, Arigoni M, Trovato R, Bolli E, Zheng Y, Ria F, Quaglino E, Iezzi M, Riccardo F, Holmgren L, Forni G, Cavallo F. Antitumor immunization of mothers delays tumor development in cancer-prone offspring. *Oncoimmunology.* 2015 Feb 3;4(5):e1005500. eCollection 2015 May. PubMed PMID: 26155401.
31. Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, Dall'Ora M, Iezzi M, De Giovanni C, Lollini PL. Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis. *Breast Cancer Res.* 2015 May 22;17:70. doi: 10.1186/s13058-015-0588-x. PubMed PMID: 25997501; PubMed Central PMCID: PMC4462012.
32. Mosley M, Knight J, Neesse A, Michl P, Iezzi M, Kersemans V, Cornelissen B. Claudin-4 SPECT Imaging Allows Detection of Aplastic Lesions in a Mouse Model of Breast Cancer. *J Nucl Med.* 2015 May;56(5):745-51. doi: 10.2967/jnumed.114.152496. Epub 2015 Apr 3. PubMed PMID: 25840973.
33. Manservigi F, Gopalakrishnan K, Tibaldi E, Hysi A, Iezzi M, Lambertini L, Teitelbaum S, Chen J, Belpoggi F. Effect of maternal exposure to endocrine disrupting chemicals on reproduction and mammary gland development in female sprague-dawley rats. *Reprod Toxicol.* 2014 Dec 29. pii: S0890-6238(14)00324-4. doi: 10.1016/j.reprotox.2014.12.013. [Epub ahead of print] PubMed PMID: 25554385.
34. Cornelissen B, Able S, Kartsonaki C, Kersemans V, Allen PD, Cavallo F, Cazier JB, Iezzi M, Knight J, Muschel R, Smart S, Vallis KA. Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer. *J Nucl Med.* 2014 Dec;55(12):2026-31. doi: 10.2967/jnumed.114.142083. Epub 2014 Nov 13. PubMed PMID: 25453049.
35. Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM. Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab. *Cancer Res.* 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27. PubMed PMID: 25164009.

36. Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. *Clin Lung Cancer*. 2014 Nov;15(6):470-4. doi: 10.1016/j.clcc.2014.06.004. Epub 2014 Jun 24. PubMed PMID: 25087901.
37. Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, Carrara M, Fiore A, Nuzzo S, Bicciato S, Nanni P, Landuzzi L, Cavallo F, Calogero R, Quagliano E. Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. *BMC Genomics*. 2014;15 Suppl 3:S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6. PubMed PMID: 25077564; PubMed Central PMCID: PMC4083401.
38. Kalogris C, Garulli C, Pietrella L, Gambini V, Pucciarelli S, Lucci C, Tilio M, Zabaleta ME, Bartolacci C, Andreani C, Giangrossi M, Iezzi M, Belletti B, Marchini C, Amici A. Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. *Biochem Pharmacol*. 2014 May 27.
39. Macagno M, Bandini S, Stramucci L, Quagliano E, Conti L, Balmas E, Smyth MJ, Lollini PL, Musiani P, Forni G, Iezzi M, Cavallo F. Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. *J Immunol*. 2014 Jun 1;192(11):5434-41. Epub 2014 Apr 30.
40. Petrarca C, Clemente E, Toto V, Iezzi M, Rossi C, Zanotta S, Mistrello G, Zanoni I, Granucci F, Arioli S, Mora D, Guglielmetti S, Paganelli R, Di Gioacchino M. rBet v 1 immunotherapy of sensitized mice with *Streptococcus thermophilus* as vehicle and adjuvant. *Hum Vaccin Immunother*. 2014 Mar 6;10(5).
41. De Giovanni C, Nicoletti G, Quagliano E, Landuzzi L, Palladini A, Ianzano ML, Dall'ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. *Breast Cancer Res*. 2014 Jan 23;16(1):R10.
42. Silvio Bandini, Claudia Curcio, Marco Macagno, Elena Quagliano, Maddalena Arigoni, Stefania Lanzardo, Albana Hysi, Giuseppina Barutello, Lorena Consolino, Dario Longo, Piero Musiani, Guido Forni, Manuela Iezzi, and Federica Cavallo. Early onset and enhanced growth of autochthonous mammary carcinomas in C3 deficient Her2/neu transgenic mice. *Oncoimmunology*. 2013 Sep 1;2(9):e26137. Epub 2013 Sep 12

43. Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Muller A, Hiebl B, Holzhausen HJ, Seliger B HER-2/neu mediates oncogenic transformation via altered CREB expression and function. *Mol Cancer Res.* 2013 Sep 11.
44. Nubile M, Curcio C, Lanzini M, Calienno R, Iezzi M, Mastropasqua A, Di Nicola M, Mastropasqua L. Expression of CREB in Primary Pterygium and Correlation with Cyclin D1, ki-67, MMP7, p53, p63, Survivin and Vimentin. *Ophthalmic Res.* 2013;50(2):99-107.
45. Conti L, Lanzardo S, Iezzi M, Montone M, Bolli E, Brioschi C, Maiocchi A, Forni G, Cavallo F. Optical imaging detection of microscopic mammary cancer in ErbB-2 transgenic mice through the DA364 probe binding $\alpha\beta3$ integrins. *Contrast Media Mol Imaging.* 2013 Jul-Aug;8(4):350-60.
46. Nubile M, Curcio C, Dua HS, Calienno R, Lanzini M, Iezzi M, Mastropasqua R, Agnifili L, Mastropasqua L. Pathological changes of the anatomical structure and markers of the limbal stem cell niche due to inflammation. *Mol Vis.* 2013;19:516-25. Epub 2013 Feb 26.
47. Nanni P., Gatta V, Menotti L., De Giovanni C., Ianzano M., Palladini A., Grosso V., Dall'Ora M., Croci S., Nicoletti G., Landuzzi L., Iezzi M., Campadelli-Fiume G., Lollini P.L. Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. *PLoS Pathog.* 2013 Jan;9(1):e1003155.
48. Bisaro B, Montani M, Konstantinidou G, Marchini C, Pietrella L, Iezzi M, Galiè M, Orso F, Camporeale A, Colombo SM, Di Stefano P, Tornillo G, Camacho-Leal MP, Turco E, Taverna D, Cabodi S, Amici A, Defilippi P. p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells. *Breast Cancer Res.* 2012 Oct 26;14(5):R137.
49. De Giovanni C, Nicoletti G, Landuzzi L, Romani F, Croci S, Palladini A, Murgo A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Iezzi M, Stramucci L, Barbieri E, Lemoli RM, Nanni P, and Lollini PL. Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. *British Journal of Cancer* 2012 Oct 9;107(8):1302-9.
50. Iezzi M, Quaglino E, Amici A, Lollini PL, Forni G, Cavallo F. DNA vaccination against oncoantigens: A promise. *Oncoimmunology.* 2012 May 1;1(3):316-325.
51. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A, Landuzzi L, di Tomaso E, Iezzi M, De Giovanni C, Lollini PL. Multiorgan Metastasis of Human HER-2(+) Breast Cancer in Rag2(-/-);Il2rg(-/-) Mice and Treatment with PI3K Inhibitor. *PLoS One.* 2012;7(6):e39626. Epub 2012 Jun 21.

52. Arigoni M, Barutello G, Lanzardo S, Longo D, Aime S, Curcio C, Iezzi M, Zheng Y, Barkefors I, Holmgren L, Cavallo F. A vaccine targeting angiominin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors. *Angiogenesis*. 2012 Jun;15(2):305-16.
53. Iezzi M, Quaglino E, Cappello P, Toto V, Sabatini F, Curcio C, Garotta G, Musiani P, Cavallo F. HCG hastens both the development of mammary carcinoma and the metastatization of HCG/LH and ERBB-2 receptor-positive cells in mice. *Int J Immunopathol Pharmacol*. 2011 Jul-Sep;24(3):621-30.
54. Berta GN, Sprio AE, Iezzi M, Spadaro M, Cappia S, Salamone P, Di Scipio F, Mognetti B, Papotti M, Musiani P, Forni G, Cavallo F. A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. *Cancer Prev Res (Phila)*. 2011 Jul;4(7):994-1001.
55. Marchini C, Gabrielli F, Iezzi M, Zenobi S, Montani M, Pietrella L, Kalogris C, Rossini A, Ciravolo V, Castagnoli L, Tagliabue E, Pupa SM, Musiani P, Monaci P, Menard S, Amici A. The human splice variant Δ 16HER2 induces rapid tumor onset in a reporter transgenic mouse. *PLoS One*. 2011 Apr 29;6(4):e18727.
56. Petrarca C, Lazzarin F, Pannellini T, Iezzi M, Braga M, Mistrello G, Falagiani P, Di Giampaolo L, Di Gioacchino M. Monomeric allergoid intragastric administration induces local and systemic tolerogenic response involving IL-10-producing CD4(+)CD25(+) T regulatory cells in mice. *Int J Immunopathol Pharmacol*. 2010 Oct-Dec;23(4):1021-31.
57. Marchini C, Montani M, Konstantinidou G, Orrù R, Mannucci S, Ramadori G, Gabrielli F, Baruzzi A, Berton G, Merigo F, Fin S, Iezzi M, Bisaro B, Sbarbati A, Zerani M, Galiè M, Amici A. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. *PLoS One*. 2010 Nov 30;5(11):e14131.
58. Pannellini T, Iezzi M, Liberatore M, Sabatini F, Iacobelli S, Rossi C, Alberti S, Di Ilio C, Vitaglione P, Fogliano V, Piantelli M. A dietary tomato supplement prevents prostate cancer in TRAMP mice. *Cancer Prev Res (Phila)*. 2010 Oct;3(10):1284-91.
59. Bono AV, Pannellini T, Liberatore M, Montironi R, Cunico SC, Cheng L, Sasso F, Musiani P, Iezzi M. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis. *Anal Quant Cytol Histol*. 2010 Jun;32(3):136-45.

60. Cabodi S, Tinnirello A, Bisaro B, Tornillo G, del Pilar Camacho-Leal M, Forni G, Cojoca R, Iezzi M, Amici A, Montani M, Eva A, Di Stefano P, Muthuswamy SK, Tarone G, Turco E, Defilippi P. p130Cas is an essential transducer element in ErbB2 transformation. *FASEB J.* 2010 Oct;24(10):3796-808.
61. Rolla S, Ria F, Occhipinti S, Di Sante G, Iezzi M, Spadaro M, Nicolò C, Ambrosino E, Merighi IF, Musiani P, Forni G, Cavallo F. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy. *J Immunol.* 2010 Jun 1;184(11):6124-32.
62. De Santis R, Leoni B, Rosi A, Albertoni C, Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M, Carminati P. AvidinOX for highly efficient tissue-pretargeted radionuclide therapy. *Cancer Biother Radiopharm.* 2010 Apr;25(2):143-8.
63. Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G, Forni G, Cavallo F. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. *Cancer Res.* 2010 Apr 1;70(7):2604-12.
64. Ciraolo E, Morello F, Hobbs RM, Wolf F, Marone R, Iezzi M, Lu X, Mengozzi G, Altruda F, Sorba G, Guan K, Pandolfi PP, Wymann MP, Hirsch E. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. *Mol Biol Cell.* 2010 Mar 1;21(5):704-11.
65. Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, Cipriani B, De Palma R, Ricci-Vitiani L, Peranzoni E, Musiani P, Zanovello P, Bronte V. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. *Blood.* 2010 Feb 18;115(7):1374-84.
66. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. *J Cell Mol Med.* 2010 Dec;14(12):2803-15.
67. De Giovanni C, Nicoletti G, Landuzzi L, Croci S, Palladini A, Antognoli A, Murgo A, Ianzano ML, Grosso V, Stivani V, Iezzi M, Musiani P, Nanni P, Lollini PL. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy. *Vaccine.* 2009 Mar 23;27(14):2065-9.
68. De Giovanni C, Nicoletti G, Palladini A, Croci S, Landuzzi L, Antognoli A, Murgo A, Astolfi A, Ferrini S, Fabbi M, Orengo AM, Amici A, Penichet ML, Aurisicchio L, Iezzi M, Musiani P, Nanni P, Lollini

- PL. A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome. *Hum Gene Ther.* 2009 May;20(5):453-64.
69. Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, Iacobelli S, Brogгинi M, Falasca M. Phospholipase Cgamma1 is required for metastasis development and progression. *Cancer Res.* 2008 Dec;68:10187-96.
70. Carmela Mennuni, Stefano Ugel, Federica Mori, Barbara Cipriani, Manuela Iezzi, Tania Pannellini, Domenico Lazzaro, Gennaro Ciliberto, Nicola La Monica, Paola Zanovello, Vincenzo Bronte, and Elisa Scarselli. Preventive Vaccination with Telomerase Controls Tumor Growth in Genetically Engineered and Carcinogen-Induced Mouse Models of Cancer. *Cancer Res.* 2008 Dec 1;68:9865-74.
71. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, Porreca E. Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/Dx-5 cells by nonsteroidal anti-inflammatory drugs. *Oncol Rep.* 2008 Oct;20(4):731-5.
72. Ciralo E, Iezzi M, Marone R, Marengo S, Curcio C, Costa C, Azzolino O, Gonella C, Rubinetto C, Wu H, Dastrù W, Martin EL, Silengo L, Altruda F, Turco E, Lanzetti L, Musiani P, Rückle T, Rommel C, Backer JM, Forni G, Wymann MP, Hirsch E. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. *Sci Signal.* 2008 Sep 9;1(36):ra3..
73. Cristina Mastini, Pablo D. Becker, Manuela Iezzi, Claudia Curcio, Piero Musiani, Guido Forni, Federica Cavallo, and Carlos A. Guzman. Intramammary Application of Non-Methylated-CpG Oligodeoxynucleotides (CpG) Inhibits both Local and Systemic Mammary Carcinogenesis in Female BALB/c Her-2/neu Transgenic Mice. *Current Cancer Drug Target.* 2008 May;8(3):230-42.
74. AV Bono, R Montironi, T Pannellini, V Mirone, P Musiani & M Iezzi. Effects of castration on the development of prostate adenocarcinoma from its precursor HGPIN and on the occurrence of androgen-independent poorly differentiated carcinoma in TRAMP mice. *Prostate Cancer Prostatic Dis.* 2008 Apr 1; [Epub ahead of print]
75. Simona Rolla, Cristina Marchini, Silvia Malinarich, Elena Quaglino, Stefania Lanzardo, Maura Montani, Manuela Iezzi, Mauro Angeletti, Giorgio Ramadori, Guido Forni, Federica Cavallo, Augusto Amici. Protective immunity against *neu+* carcinomas elicited by electroporation of

plasmids coding for decreasing fragments of rat *neu* extracellular domain. Hum Gene Ther. 2008 Mar;19:229-40.

76. Patrizia Nanni, Giordano Nicoletti, Arianna Palladini, Stefania Croci, Annalisa Murgio, Agnese Antognoli, Lorena Landuzzi, Marina Fabbi, Silvano Ferrini, Piero Musiani, Manuela Iezzi, Carla De Giovanni and Pier-Luigi Lollini. Antimetastatic activity of a preventive cancer vaccine. Cancer Res. 2007; 67:11037-44.
77. Shayna E. A. Street, Nadeen Zerafa, Manuela Iezzi, Jennifer A. Westwood, John Stagg, Piero Musiani and Mark J. Smyth. Host perforin reduces tumor number but does not increase survival in oncogene driven mammary adenocarcinoma. Cancer Res. 2007; 67:5454-60.
78. De Giovanni C, Croci S, Nicoletti G, Landuzzi L, Palladini A, Pannellini T, Borgia L, Iezzi M, Di Carlo E, Orengo AM, Kennedy RC, Lollini PL, Nanni P, Musiani P. Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. Int J Cancer. 2007;121:88-94.
79. Claudia Chiodoni, Manuela Iezzi, Cristiana Guiducci, Sabina Sangaletti, Isabella Alessandrini, Chiara Ratti, Francesca Tiboni, Piero Musiani, D. Neil Granger, and Mario P. Colombo. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006; 203:2441-50.
80. Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D'Antonio D, Piccolomini R. Biofilm Formation by the Emerging Fungal Pathogen *Trichosporon asahii*: Development, Architecture, and Antifungal Resistance. Antimicrob Agents Chemother. 2006; 50:3269-76.
81. Elena Ambrosino, Michela Spadaro, Manuela Iezzi, Claudia Curcio, Guido Forni, Piero Musiani, Wei-Zen Wei and Federica Cavallo. Immunosurveillance of ErbB2 Carcinogenesis in Transgenic Mice Is Concealed by a Dominant Regulatory T-Cell Self-Tolerance. Cancer Res. 2006; 66:7734-40.
82. Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmaki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R. A DNA vaccine targeting angiominin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A. 2006; 103:9208-13.
83. Pannellini T, Spadaro M, Di Carlo E, Ambrosino E, Iezzi M, Amici A, Lollini PL, Forni G, Cavallo F, Musiani P. Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression. J Immunol. 2006; 176:7695-7703.

84. Piantelli M, Rossi C, Iezzi M, La Sorda R, Iacobelli S, Alberti S, Natali PG. Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. *J Cell Physiol.* 2006; 207:23-9.
85. Cavallo F, Astolfi A, Iezzi M, Cordero F, Lollini PL, Forni G, Calogero R. An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. *BMC Bioinformatics.* 2005; 6 Suppl 4:S7.
86. Zerafa N, Westwood JA, Cretney E, Mitchell S, Waring P, Iezzi M, Smyth MJ. Cutting Edge: TRAIL Deficiency Accelerates Hematological Malignancies. *J Immunol.* 2005; 175:5586-90.
87. Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C, Broggin M, Iacobelli S, Potter BV, Innocenti P, Falasca M. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. *Cancer Res.* 2005; 65:8339-49.
88. Maddalo G, Petrucci F, Iezzi M, Pannellini T, Del Boccio P, Ciavardelli D, Biroccio A, Forli F, Di Ilio C, Ballone E, Urbani A, Federici G. Analytical assessment of MALDI-TOF Imaging Mass Spectrometry on thin histological samples. An insight in proteome investigation. *Clin Chim Acta.* 2005; 357:210-8.
89. Lo Iacono M, Cavallo F, Quaglino E, Rolla S, Iezzi M, Pupa SM, De Giovanni C, Lollini PL, Musiani P, Forni G, Calogero RA. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. *Int J Immunopathol Pharmacol.* 2005; 18:351-63.
90. Quaglino E, Mastini C, Iezzi M, Forni G, Musiani P, Klapper LN, Hardy B, Cavallo F. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. *Vaccine.* 2005; 23:3280-7.
91. Astolfi A, Landuzzi L, Nicoletti G, De Giovanni C, Croci S, Palladini A, Ferrini S, Iezzi M, Musiani P, Cavallo F, Forni G, Nanni P, Lollini PL. Gene Expression Analysis of Immune-Mediated Arrest of Tumorigenesis in a Transgenic Mouse Model of HER-2/neu-Positive Basal-Like Mammary Carcinoma. *Am J Pathol.* 2005; 166:1205-16
92. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, Amici A, Wei WZ, Musiani P, Lollini PL, Cavallo F, Forni G. Cure of mammary carcinomas in Her-2 transgenic mice through

sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. *Clin Cancer Res.* 2005; 11:1941-52.

93. De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. *Proc Natl Acad Sci U S A.* 2005; 102:4185-90.
94. Pupa SM, Iezzi M, Di Carlo E, Invernizzi A, Cavallo F, Meazza R, Comes A, Ferrini S, Musiani P, Menard S. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. *Cancer Res.* 2005; 65:1071-8.
95. Astolfi A, Rolla S, Nanni P, Quaglino E, De Giovanni C, Iezzi M, Musiani P, Forni G, Lollini PL, Cavallo F, Calogero RA. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. *Cancer Immunol Immunother.* 2005; 54:599-610.
96. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F, Musiani P, Forni G, Monaci P. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. *Int J Cancer.* 2005; 113:67-77.
97. Nanni P, Landuzzi L, Nicoletti G, De Giovanni C, Rossi I, Croci S, Astolfi A, Iezzi M, Di Carlo E, Musiani P, Forni G, Lollini PL. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent. *J Immunol.* 2004; 173:2288-96.
98. De Giovanni C, Nicoletti G, Landuzzi L, Astolfi A, Croci S, Comes A, Ferrini S, Meazza R, Iezzi M, Di Carlo E, Musiani P, Cavallo F, Nanni P, Lollini PL. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine. *Cancer Res.* 2004; 64:4001-9.
99. Pannellini T, Iezzi M, Di Carlo E, Eleuterio E, Coletti A, Modesti A, Rosini S, Neri M, Musiani P. The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis. *Int J Immunopathol Pharmacol.* 2004; 17:171-80.
100. Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. *Cancer Res.* 2004; 64:2858-64.
101. Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R, Cavallo F. Concordant morphologic and gene

- expression data show that a vaccine halts HER-2/neu preneoplastic lesions. *J Clin Invest.* 2004; 113:709-17.
- 102.Nanni P, Nicoletti G, De Giovanni C, Croci S, Astolfi A, Landuzzi L, Di Carlo E, Iezzi M, Musiani P, Lollini PL. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. *Cancer Res.* 2003; 63:2728-32.
- 103.Cappello P, Triebel F, Iezzi M, Caorsi C, Quaglino E, Lollini PL, Amici A, Di Carlo E, Musiani P, Giovarelli M, Forni G. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. *Cancer Res.* 2003; 63:2518-25.
- 104.Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Iezzi M, Ricci C, Astolfi A, Croci S, Marangoni F, Musiani P, Forni G, Lollini PL. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. *Int J Cancer.* 2003; 105:384-9.
- 105.Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L, Ranelletti FO. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. *J Clin Oncol.* 2002; 20:3850-6.
- 106.Gavallo F, Carlo ED, Quaglin E, Jezzi M, Strasly M, Bussolino F, Colombo MP, Nanni P, Lollini PL, Musiani P, Forni G. Prevention by delay: nonspecific immunity elicited by IL-12 hinders Her-2/neu mammary carcinogenesis in transgenic mice. *J Biol Regul Homeost Agents.* 2001; 15:351-8.
- 107.Di Carlo E, Iezzi M, Pannellini T, Zaccardi F, Modesti A, Forni G, Musiani P. Neutrophils in anti-cancer immunological strategies: old players in new games. *J Hematother Stem Cell Res.* 2001; 10:739-48.
- 108.Diodoro MG, Di Carlo E, Zappacosta R, Iezzi M, Coletti A, Modesti A, D'Antuono T, Forni G, Musiani P. Salivary carcinoma in HER-2/neu transgenic male mice: an angiogenic switch is not required for tumor onset and progression. *Int J Cancer.* 2000; 88:329-35.
- 109.Morelli L, Di Giulio C, Iezzi M, Data PG. Effect of acute and chronic cobalt administration on carotid body chemoreceptors responses. *Sci Total Environ.* 1994; 150:215-6.
- 110.Data PG, Di Tano G, Gigante G, Biondelli V, Iezzi M, Di Giulio C, Morelli L. Effects of chronic hypoxia and cobalt on macroprotein pattern in the rabbit carotid body and superior cervical ganglion: preliminary observations. *Adv Exp Med Biol.* 1993; 337:401-5.